We delineated the emerging evidence highlighting the roles of AP-2 family members in obesity, type 2 diabetes, gastrointestinal dysmotility, and esophageal squamous cell cancer, thereby suggesting a potential therapeutic avenue for these disorders. This evidence concerns the gene TFAP2A and Obesity.